Zelluna ASA (OSTO:ULTIO) Total Liabilities: kr8.80 Mil (As of Mar. 2026)


OSTO:ULTIO Zelluna ASA OSTO:ULTIO
28 GF Score
Price kr21.95
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA Total Liabilities?

Zelluna ASA OSTO:ULTIO 28 Total Liabilities is kr8.80 Mil as of Mar. 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Zelluna ASA's Total Liabilities for the quarter that ended in Mar. 2026 was kr8.80 Mil.

Zelluna ASA's quarterly Total Liabilities declined from Sep. 2025 (kr16.06 Mil) to Dec. 2025 (kr7.65 Mil) but then increased from Dec. 2025 (kr7.65 Mil) to Mar. 2026 (kr8.80 Mil).

Zelluna ASA's annual Total Liabilities declined from Dec. 2023 (kr69.65 Mil) to Dec. 2024 (kr32.52 Mil) and declined from Dec. 2024 (kr32.52 Mil) to Dec. 2025 (kr7.65 Mil).


Zelluna ASA Total Liabilities Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA Total Liabilities Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.38 60.32 69.65 32.52 7.65

Zelluna ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.51 23.71 16.06 7.65 8.80
OSTO:ULTIO
28GF Score
Zelluna ASA OSTO:ULTIO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zelluna ASA's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.65+(0+-0.0010000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.65

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=308.07-300.421
=7.65

Zelluna ASA's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=75.838-67.036
=8.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr8.80 Mil mean?
Zelluna ASA (OSTO:ULTIO) has a Total Liabilities of kr8.80 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zelluna ASA and its competitors.
Is Zelluna ASA's Total Liabilities too high?
Zelluna ASA's current Total Liabilities is kr8.80 Mil. Overall, Zelluna ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Total Liabilities compare to VRTX and REGN?
Zelluna ASA's Total Liabilities of kr8.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zelluna ASA and its competitors. Zelluna ASA's current Total Liabilities is kr8.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current Total Liabilities of kr8.80 Mil. The current Total Liabilities is kr8.80 Mil. Zelluna ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current Total Liabilities is kr8.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway7UM0:Germany
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
28GF Score

Get the complete analysis for OSTO:ULTIO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95
Price